486 related articles for article (PubMed ID: 33054456)
21. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
[TBL] [Abstract][Full Text] [Related]
22. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
23. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.
Rengan AK; Denlinger CS
J Natl Compr Canc Netw; 2022 Apr; 20(5):430-435. PubMed ID: 35378504
[TBL] [Abstract][Full Text] [Related]
24. FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A; Segatto O; Stenzinger A; Saborowski A
Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
[TBL] [Abstract][Full Text] [Related]
25. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
[TBL] [Abstract][Full Text] [Related]
26. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
[TBL] [Abstract][Full Text] [Related]
27. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
[TBL] [Abstract][Full Text] [Related]
29. The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma.
Ruff SM; Roychowdhury S; Pawlik TM
Expert Opin Pharmacother; 2023 May; 24(7):779-788. PubMed ID: 37042129
[TBL] [Abstract][Full Text] [Related]
30. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
Sahin IH; Tan E; Kim R
Expert Opin Investig Drugs; 2021 Apr; 30(4):333-341. PubMed ID: 33378249
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
[TBL] [Abstract][Full Text] [Related]
32.
Cleary JM; Raghavan S; Wu Q; Li YY; Spurr LF; Gupta HV; Rubinson DA; Fetter IJ; Hornick JL; Nowak JA; Siravegna G; Goyal L; Shi L; Brais LK; Loftus M; Shinagare AB; Abrams TA; Clancy TE; Wang J; Patel AK; Brichory F; Vaslin Chessex A; Sullivan RJ; Keller RB; Denning S; Hill ER; Shapiro GI; Pokorska-Bocci A; Zanna C; Ng K; Schrag D; Jänne PA; Hahn WC; Cherniack AD; Corcoran RB; Meyerson M; Daina A; Zoete V; Bardeesy N; Wolpin BM
Cancer Discov; 2021 Oct; 11(10):2488-2505. PubMed ID: 33926920
[TBL] [Abstract][Full Text] [Related]
33. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
Rizzo A
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
[TBL] [Abstract][Full Text] [Related]
34. Polyclonal Secondary
Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX
Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880
[TBL] [Abstract][Full Text] [Related]
35. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
Ang C
J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
[TBL] [Abstract][Full Text] [Related]
36. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
Bath NM; Pawlik TM
Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
Saridogan T; Akcakanat A; Zhao M; Evans KW; Yuca E; Scott S; Kirby BP; Zheng X; Ha MJ; Chen H; Ng PKS; DiPeri TP; Mills GB; Rodon Ahnert J; Damodaran S; Meric-Bernstam F
Sci Rep; 2023 Nov; 13(1):20223. PubMed ID: 37980453
[TBL] [Abstract][Full Text] [Related]
38. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
Saborowski A; Vogel A; Segatto O
Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
[TBL] [Abstract][Full Text] [Related]
39. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
[TBL] [Abstract][Full Text] [Related]
40. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs.
Marin JJ; Macias RI
Expert Opin Investig Drugs; 2021 Jul; 30(7):675-679. PubMed ID: 33934687
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]